HG204 represents a novel therapeutic approach for MECP2 Duplication Syndrome (MDS), a rare neurodevelopmental disorder primarily affecting males. The potential market for HG204 is significant, given the lack of curative therapies and the severe impact of MDS on patients and families. The successful development of HG204 could position HuidaGene Therapeutics as a leader in gene-editing therapies for rare diseases, particularly in the context of CRISPR technology. Competitive analysis indicates that while there are other gene therapies in development, HG204's unique mechanism of action and delivery method may provide a distinct advantage. Diligence should focus on regulatory pathways, especially considering the innovative nature of the therapy and the need for robust safety and efficacy data.